Related references
Note: Only part of the references are listed.An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
Sayer Al-Harbi et al.
BLOOD (2011)
BH3-only Activator Proteins Bid and Bim Are Dispensable for Bak/Bax-dependent Thrombocyte Apoptosis Induced by Bcl-xL Deficiency MOLECULAR REQUISITES FOR THE MITOCHONDRIAL PATHWAY TO APOPTOSIS IN PLATELETS
Takahiro Kodama et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells
Alyson J. Smith et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Global gene disruption in human cells to assign genes to phenotypes by deep sequencing
Jan E. Carette et al.
NATURE BIOTECHNOLOGY (2011)
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim
Lina Happo et al.
BLOOD (2010)
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies et al.
BLOOD (2010)
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma
Gaofeng Fan et al.
BLOOD (2010)
Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
Stephen K. Tahir et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The BCL-2 Family Reunion
Jerry E. Chipuk et al.
MOLECULAR CELL (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA
Angela M. Keuling et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
Decheng Ren et al.
SCIENCE (2010)
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler et al.
BLOOD (2009)
Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors
Kate F. Whitecross et al.
BLOOD (2009)
Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
Shuang Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells
Arnim Weber et al.
TRANSLATIONAL ONCOLOGY (2009)
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Mark S. Cragg et al.
NATURE REVIEWS CANCER (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax
Jonathan F. Lovell et al.
CELL (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
Mikhail A. Nikiforov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents
Jing Deng et al.
CANCER CELL (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation
Shuang Chen et al.
CANCER RESEARCH (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
BH3-only proteins in cell death initiation, malignant disease and anticancer therapy
V. Labi et al.
CELL DEATH AND DIFFERENTIATION (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
Analysis of apoptosis by propidium iodide staining and flow cytometry
Carlo Riccardi et al.
NATURE PROTOCOLS (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis
Q Zhong et al.
CELL (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens
AB Werner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai et al.
CANCER CELL (2002)
Evaluation of the relative contribution of p53-mediated pathway in X-ray-induced apoptosis in human leukemic MOLT-4 cells by transfection with a mutant p53 gene at different expression levels
H Nakano et al.
CELL AND TISSUE RESEARCH (2001)
Share Paper
